查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995380

医疗相关感染疾病诊断市场：依检测方法、病原体类型、检体类型和最终用户划分－2026-2032年全球市场预测

Healthcare-associated Infectious Disease Diagnostics Market by Test Method, Pathogen Type, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医疗保健相关感染疾病诊断市场价值将达到 276.6 亿美元，到 2026 年将成长至 298.2 亿美元，到 2032 年将达到 497.7 亿美元，复合年增长率为 8.75%。

主要市场统计数据
基准年 2025 276.6亿美元
预计年份：2026年 298.2亿美元
预测年份 2032 497.7亿美元
复合年增长率 (%) 8.75%

为了抑制医疗相关感染疾病并提高病患安全，我们将概述在推广下一代诊断技术方面面临的紧迫的临床、营运和政策挑战。

医疗相关感染疾病对临床医生、实验室技术人员和医疗系统而言始终是持续且不断变化的挑战。快速且准确的诊断是及时进行病患管理、合理使用抗生素和实施感染预防计画的关键。随着临床路径的日益整合和住院容量压力的增加，诊断效能和工作流程的兼容性正成为医疗服务中日益重要的因素。

本研究检验了正在重塑整个医疗保健环境中的诊断工作流程、检查室实践和感染预防策略的变革性技术、监管和行为变化。

技术进步、监管环境的变化以及不断涌现的临床需求正在从根本上改变我们的诊断方式。分子诊断已从专业参考检查室转移到以患者为中心的医疗机构，从而能够早期检测病原体并快速制定治疗策略。同时，免疫检测平台也在不断发展，自动化程度和连接性不断提高，减少了人工操作，并在高通量环境下提高了结果的可重复性。

本研究分析了 2025 年美国关税措施对供应链、价格趋势、製造地决策和临床采购行为的多方面影响。

关税措施和贸易政策的变化会对整个诊断供应链产生连锁反应，影响零件、耗材和组装设备。 2025年，关税体系的变化影响了试剂生产商和设备组装的采购决策，促使一些机构实现供应商多元化并重新评估其库存策略。对于检查室管理人员和采购团队而言，这些变化使得他们在保持检测能力不间断的同时，更加重视成本控制。

我们提供清晰的细分见解，将检测方法、病原体特异性诊断、终端用户检测能力和检体类型考虑因素与临床效用和营运规划联繫起来。

详细的市场区隔分析能够提供切实可行的洞察，帮助我们了解价值创造的来源以及可能出现营运摩擦的环节。从检测方法来看，市场可细分为免疫检测、微生物学、分子诊断学三大类。免疫检测包括化学化学冷光免疫检测、酵素连结免疫吸附试验 (ELISA) 和侧向流动免疫分析，每种方法在处理能力、灵敏度和易用性方面各有专注。微生物学工作流程包括培养、显微镜检查和药敏试验，其中培养可进一步细分为需氧培养和厌氧培养，这会影响检查室布局和培养通讯协定。分子横向流动化验包括等温扩增、聚合酶炼式反应 (PCR) 和定序方法，每种方法都有其独特的基础设施、负责人配置和资料解读要求。

本报告分析了美洲、欧洲、中东和非洲以及亚太地区的区域趋势，并指出了测试能力、部署模式和战略市场进入考量的优势。

区域趋势对诊断技术的应用、监管协调和供应链发展有显着影响。在美洲，成熟的检查室基础设施和完善的报销机制催生了对快速、高通量解决方案和患者现场检测的需求。该地区的相关人员通常优先考虑整合性、扩充性和供应商支援。相较之下，欧洲、中东和非洲（EMEA）的情况则较为复杂，监管差异、资源限制和不同的公共卫生优先事项导致了不同的应用模式。在许多市场，集中式参考检测和满足紧急需求的快速就地检验在局部并存。

我们分析主要企业及其竞争行为，以揭示影响诊断生态系统的产品系列、伙伴关係策略、创新管道和商业化方法。

企业行为和竞争定位对于决定医疗保健领域诊断能力的演变至关重要。主要企业正专注于采用组合式策略，平衡高通量检查室系统、即时检测平台和接近专利保护的平台，从而兼顾集中式检测的经济效益和分散式临床需求。策略伙伴关係和分销协议正在拓展地域覆盖范围，并支援在地化服务交付；而创新研发管线则体现了多实验室能力、自动化和数位化连接等优先事项。

产业领导者提供切实可行的建议，以优化诊断系统部署、增强供应弹性，并使临床工作流程与感染控制要求保持一致。

针对行业领导者的实用建议必须将策略洞察转化为采购、检查室营运和临床管治方面的可操作步骤。首先，在评估新平台时，应优先考虑互通性和连接性，确保检测结果与电子健康记录、决策支援工具和监测系统无缝整合。这有助于减轻临床医生的认知负担，并支持药物管理计划。其次，供应链风险评估应纳入采购流程，评估替代试剂来源、前置作业时间差异以及供应商紧急时应对计画，以避免在供应紧张时期出现服务中断。

为了支持可靠的研究结果，我们描述了一种严谨的混合方法调查方法，该方法结合了对关键相关人员的访谈、对检查室工作流程的观察以及对二手证据的整合。

本分析采用混合研究方法，整合了来自一手和二手调查的数据，以得出可操作的见解。主要定性资料是透过对实验室管理人员、感染疾病医生、采购负责人和监管专家进行结构化访谈收集的，旨在了解实际操作情况、未解决的需求以及实施障碍。除访谈外，对不同环境下的检查室工作流程进行直接观察，有助于了解分析前阶段的差异性、能力限制和整合挑战。

将关键见解整合为连贯的策略建议，供医疗保健领导者、检查室管理者和政策制定者参考。

这份总结性的综合分析将研究结果提炼为针对医疗保健领导者、检查室管理者和政策制定者的策略建议。诊断技术只有在能够及时提供临床决策所需的有效信息，并且检查室工作流程能够持续产出高品质、及时的结果时，才能发挥最大效用。技术创新，特别是分子诊断和自动化免疫检测领域的创新，为转变诊断模式提供了契机，但成功实施需要互通性、充足的人力资源和稳健的供应链。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按检测方法分類的医疗相关感染疾病诊断市场

  • 免疫检测
    • 化学冷光免疫检测
    • ELISA
    • 横向流动化验
  • 微生物学
    • 文化
      • 需氧培养
      • 厌氧培养
    • 显微镜检查
    • 敏感性测试
  • 分子诊断
    • 等温扩增
    • PCR
    • 定序

第九章：按病原体分類的医疗保健相关感染疾病诊断市场

  • 细菌
    • 困难梭状芽孢桿菌
    • 大肠桿菌
    • 铜绿假单胞菌
    • 金黄色葡萄球菌
  • 真菌
    • 曲菌属
    • 念珠菌属
    • 新型隐球菌
  • 寄生虫
    • 疟疾原虫
    • 弓形虫
  • 病毒性的
    • 新冠病毒
    • 流感病毒
    • 诺罗病毒
    • 呼吸道融合细胞病毒

第十章：医疗相关感染疾病诊断市场－检体类型

  • 血
    • 血清
    • 全血
  • 脑脊髓液
  • 呼吸系统
    • 支气管肺泡灌洗液
    • 鼻咽拭子
    • 痰
  • 尿
    • 透过导尿管收集尿液
    • 中段尿
  • 伤口拭子
    • 深层组织检体
    • 表面拭子

第十一章：医疗保健相关感染疾病诊断市场：以最终用户划分

  • 诊断检查室
    • 独立检测实验室
    • 参考检测实验室
  • 医院
    • 临床病理检查室
    • 微生物检查室
  • 护理点
    • 诊所
    • 急诊室
    • 长期照护机构

第十二章：医疗保健相关感染疾病诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：医疗保健相关感染疾病诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：医疗保健相关感染疾病诊断市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国医疗保健相关感染疾病诊断市场

第十六章：中国医疗相关感染疾病诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-8760467AA424

The Healthcare-associated Infectious Disease Diagnostics Market was valued at USD 27.66 billion in 2025 and is projected to grow to USD 29.82 billion in 2026, with a CAGR of 8.75%, reaching USD 49.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.66 billion
Estimated Year [2026] USD 29.82 billion
Forecast Year [2032] USD 49.77 billion
CAGR (%) 8.75%

Framing the urgent clinical, operational, and policy imperatives driving next-generation diagnostic adoption to curb healthcare-associated infections and improve patient safety outcomes

Healthcare-associated infectious diseases represent a persistent and evolving challenge for clinicians, laboratory professionals, and health systems alike. Rapid and accurate diagnostics are core to timely patient management, antimicrobial stewardship, and infection prevention programs. As clinical pathways become more integrated and pressure on inpatient capacity intensifies, diagnostic performance and workflow fit are increasingly decisive factors in care delivery.

This introduction frames the diagnostic landscape through three interlocking lenses: clinical utility, operational feasibility, and policy alignment. Clinicians require actionable results that inform immediate treatment decisions. Laboratory managers must balance throughput, turnaround time, and cost while maintaining rigorous quality controls. Policy makers and infection control leaders need data that supports programmatic interventions and aligns with reimbursement and regulatory imperatives.

Consequently, the diagnostics ecosystem is no longer judged by analytic sensitivity alone; it is evaluated by its ability to integrate into electronic medical records, to support antimicrobial stewardship objectives, and to withstand supply chain disruption. This synthesis sets the stage for deeper analysis of technological shifts, regulatory currents, commercial responses, and pragmatic recommendations that follow in subsequent sections.

Examining the transformative technological, regulatory, and behavioral shifts reshaping diagnostic workflows, laboratory practices, and infection prevention strategies across care settings

The diagnostic landscape is undergoing a profound transformation driven by converging technological advances, shifting regulatory expectations, and newly elevated clinical demands. Molecular methods have moved from specialized reference labs into near-patient settings, enabling earlier detection of pathogens and faster therapeutic alignment. At the same time, immunoassay platforms are evolving to offer greater automation and connectivity, reducing manual steps and enhancing reproducibility across high-throughput environments.

Regulatory frameworks and quality expectations have evolved to prioritize clinical validation and real-world performance, which influences how vendors design trials and how laboratories implement new assays. Behavioral shifts among clinicians-driven by heightened awareness of antimicrobial resistance and infection prevention targets-have increased demand for diagnostics that deliver timely, actionable intelligence rather than isolated analytic results.

Operationally, automation and digital integration are reshaping laboratory workflows, creating opportunities to reassign skilled staff to higher-value tasks while standardizing processes to improve reliability. These dynamics collectively point to a landscape in which diagnostics are evaluated not only on accuracy but on how they accelerate care, reduce inappropriate antimicrobial use, and enhance system resilience.

Analyzing the multifaceted implications of United States tariff actions in 2025 on supply chains, pricing dynamics, manufacturing location decisions, and clinical procurement behaviors

Tariff actions and trade policy changes have the potential to reverberate through diagnostic supply chains, affecting components, consumables, and assembled instruments. In 2025, shifts in tariff regimes influenced sourcing decisions for reagent manufacturers and instrument assemblers, prompting some organizations to reassess supplier diversification and inventory strategies. For laboratory managers and procurement teams, these developments brought renewed attention to cost containment while maintaining uninterrupted testing capacity.

Manufacturers responded through a range of mitigation strategies, including near-shoring certain production stages, optimizing bill-of-materials to reduce exposed components, and negotiating long-term supplier contracts to stabilize input pricing. Meanwhile, clinical stakeholders emphasized the importance of validated alternatives and cross-validated workflows to ensure clinical continuity when preferred test kits are constrained.

The broader implication is that policy shifts can accelerate structural change across the diagnostics ecosystem. In response, health systems and laboratory networks are increasingly incorporating supply-chain risk assessments into technology adoption decisions, embedding contingency plans into procurement contracts, and advocating for clarity in trade policy to reduce operational uncertainty.

Delivering incisive segmentation insights that connect test methodologies, pathogen-specific diagnostics, end user capacities, and sample type considerations to clinical utility and operational planning

A granular view of segmentation offers practical insight into where value is created and where operational friction can arise. By test method, the landscape divides among immunoassays, microbiology, and molecular diagnostics. Immunoassays encompass chemiluminescent immunoassays, ELISA, and lateral flow assays, each offering different balances of throughput, sensitivity, and ease of use. Microbiology workflows include culture, microscopy, and sensitivity testing, with culture further differentiated into aerobic and anaerobic techniques that influence laboratory layout and incubation protocols. Molecular diagnostics feature isothermal amplification, PCR, and sequencing approaches; each method carries distinct infrastructure, personnel competency, and data-interpretation requirements.

When considering pathogen type, diagnostic strategies differ for bacterial, fungal, parasitic, and viral agents. Bacterial testing frequently targets organisms such as Clostridium difficile, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus, where rapid identification and susceptibility insights directly affect antimicrobial therapy. Fungal diagnostics address Aspergillus species, Candida species, and Cryptococcus neoformans, which often require specialized assays and clinical correlation. Parasitic testing, including malaria parasites and Toxoplasma gondii, tends to be concentrated in specific clinical contexts, while viral testing for agents such as coronaviruses, influenza viruses, norovirus, and respiratory syncytial virus spans both routine surveillance and acute care decision-making.

End user characteristics shape adoption and implementation pathways. Diagnostic laboratories, including both independent and reference labs, prioritize scale, accreditation, and inter-laboratory comparability, whereas hospitals, through clinical pathology and microbiology laboratories, emphasize integration with clinical teams and rapid inpatient workflows. Point-of-care contexts such as clinics, emergency departments, and long-term care facilities demand compact platforms, simplified workflows, and rapid turnaround, which in turn influence assay format choices and validation strategies.

Sample type considerations-blood (serum and whole blood), cerebrospinal fluid, respiratory specimens (bronchoalveolar lavage, nasopharyngeal swabs, sputum), urine (catheterized and midstream), and wound swabs (deep tissue and surface swabs)-further dictate pre-analytical controls, transport logistics, and analytic sensitivity thresholds. The interplay among test method, pathogen target, end user, and sample type creates a multidimensional decision matrix that stakeholders must navigate when prioritizing investments, selecting platforms, and designing implementation pathways.

Interpreting regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific to reveal capacity strengths, adoption patterns, and strategic market entry considerations

Regional dynamics materially affect diagnostic adoption, regulatory alignment, and supply chain architecture. In the Americas, maturity in laboratory infrastructure and established reimbursement pathways create a demand environment for rapid, high-throughput solutions alongside near-patient testing; stakeholders here often prioritize integration, scalability, and vendor support models. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory variation, resource constraints, and diverse public health priorities drive differential adoption patterns; in many markets, centralized reference testing coexists with pockets of rapid point-of-care rollouts in response to acute needs.

Asia-Pacific is characterized by a wide range of capabilities, from highly advanced metropolitan laboratory networks to regions with limited access to complex platforms. This diversity shapes manufacturer strategies around modular systems, language-appropriate software, and local partnerships to ensure adoption and serviceability. Across all regions, procurement behaviors, public health imperatives, and infrastructure investments influence how diagnostics are prioritized, with connectivity and data interoperability increasingly seen as cross-cutting enablers for regional surveillance and clinical decision-making.

Consequently, strategic entry and scale-up decisions must reconcile regional regulatory pathways, logistics constraints, and clinical practice norms with the technical attributes of targeted diagnostic solutions. Stakeholders that align product offerings with regional operational realities are better positioned to achieve sustained clinical uptake and system impact.

Profiling leading companies and competitive behaviors to highlight product portfolios, partnership strategies, innovation pipelines, and commercialization approaches that influence diagnostic ecosystems

Company behavior and competitive positioning are central determinants of how diagnostic capabilities evolve across care settings. Leading manufacturers emphasize a portfolio approach that balances high-throughput laboratory systems with point-of-care and near-patient platforms, thereby addressing both centralized testing economies and decentralized clinical demands. Strategic partnerships and distribution agreements expand geographic reach and provide local serviceability, while innovation pipelines reflect priorities such as multiplexing capability, automation, and digital connectivity.

Product differentiation increasingly hinges on end-to-end value propositions: not only the analytic performance of assays but also instrumentation uptime, consumable logistics, cloud-enabled data interpretation, and training programs for laboratory staff. Firms that invest in robust post-market evidence generation and that collaborate with health systems on implementation pilots secure credibility with clinical users and procurement teams. Additionally, a competitive emphasis on sustainability-through reduced single-use plastics and optimized reagent packaging-affects procurement preferences and long-term relationship management.

As commercial players adapt to evolving policy environments and supply-chain pressures, their strategic choices around manufacturing footprints, platform modularity, and service ecosystems will determine how readily health systems can deploy and scale diagnostic solutions in pursuit of improved infection management.

Presenting actionable, high-impact recommendations for industry leaders to optimize diagnostic deployment, strengthen supply resilience, and align clinical workflows with infection control imperatives

Actionable recommendations for industry leaders must translate strategic insight into implementable steps across procurement, laboratory operations, and clinical governance. First, prioritize interoperability and connectivity when evaluating new platforms so results can seamlessly integrate with electronic medical records, decision support tools, and surveillance systems; this reduces cognitive load on clinicians and supports stewardship programs. Second, embed supply-chain risk assessments into procurement cycles by evaluating alternate reagent sources, lead-time variability, and vendor contingency plans to avoid service disruptions during periods of constrained supply.

Third, standardize validation and verification protocols across networked laboratories to enable rapid scale-up of new assays while maintaining comparability and quality assurance. Fourth, invest in workforce development to ensure laboratory staff are trained in molecular and digital workflows; reallocating staff from repetitive tasks to higher-value data interpretation improves system resilience. Fifth, adopt a phased implementation approach for novel diagnostics that includes clinical pilots, multidisciplinary reviews, and feedback loops that capture real-world performance and workflow impact.

Finally, align commercial contracting with outcomes-oriented metrics where feasible, incorporating uptime guarantees, bundled service offerings, and joint post-market evidence generation to de-risk adoption for health system customers. Taken together, these steps will accelerate responsible deployment of diagnostic innovations that materially reduce infection-related harms.

Explaining a rigorous mixed-methods research methodology combining primary stakeholder interviews, laboratory workflow observations, and secondary evidence synthesis to underpin credible findings

This analysis is grounded in a mixed-methods research approach that synthesizes primary and secondary evidence to generate actionable insight. Primary qualitative data were gathered through structured interviews with laboratory directors, infectious disease clinicians, procurement officers, and regulatory experts to capture operational realities, unmet needs, and adoption barriers. These interviews were complemented by direct observations of laboratory workflows in diverse settings to understand pre-analytical variability, throughput constraints, and integration challenges.

Secondary evidence was curated from peer-reviewed literature, regulatory guidance documents, and manufacturer technical specifications to validate assay attributes and to triangulate performance claims. Where possible, comparative assessments leveraged published analytic performance metrics and documented implementation case studies to inform practical considerations around training, maintenance, and connectivity.

Analytic rigor was maintained through standardized interview guides, cross-validation of thematic coding, and transparent documentation of assumptions used in interpretive synthesis. The resulting methodology privileges operational relevance and clinical applicability, ensuring that conclusions are actionable for decision-makers responsible for procurement, laboratory operations, and infection control policy.

Concluding synthesis that distills key insights into coherent strategic takeaways aimed at healthcare leaders, laboratory managers, and policy makers for decisive action

This concluding synthesis distills the analysis into strategic takeaways for healthcare leaders, laboratory managers, and policy makers. Diagnostics are most impactful when they deliver actionable intelligence within clinical decision windows and when laboratory workflows are designed to sustain high-quality, timely outputs. Technological innovation-particularly in molecular methods and automated immunoassays-creates opportunities to shift diagnostic paradigms, but successful adoption depends on interoperability, workforce readiness, and supply-chain robustness.

Policy and procurement levers can accelerate deployment when they incentivize real-world evidence generation, support workforce development, and incorporate contingency planning into contracts. Regional dynamics and end-user characteristics matter: solutions that are technically excellent but misaligned with local workflow, regulatory realities, or sample logistics will struggle to achieve sustained uptake. Therefore, a holistic approach that aligns clinical needs, laboratory capabilities, and commercial models is essential for delivering measurable improvements in infection prevention and patient outcomes.

Taken together, the findings underscore that integrated planning, cross-functional collaboration, and adaptive procurement strategies are central to translating diagnostic innovation into clinical and operational impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Healthcare-associated Infectious Disease Diagnostics Market, by Test Method

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescent Immunoassay
    • 8.1.2. ELISA
    • 8.1.3. Lateral Flow Assays
  • 8.2. Microbiology
    • 8.2.1. Culture
      • 8.2.1.1. Aerobic Culture
      • 8.2.1.2. Anaerobic Culture
    • 8.2.2. Microscopy
    • 8.2.3. Sensitivity Testing
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. PCR
    • 8.3.3. Sequencing

9. Healthcare-associated Infectious Disease Diagnostics Market, by Pathogen Type

  • 9.1. Bacterial
    • 9.1.1. Clostridium Difficile
    • 9.1.2. Escherichia Coli
    • 9.1.3. Pseudomonas Aeruginosa
    • 9.1.4. Staphylococcus Aureus
  • 9.2. Fungal
    • 9.2.1. Aspergillus Species
    • 9.2.2. Candida Species
    • 9.2.3. Cryptococcus Neoformans
  • 9.3. Parasitic
    • 9.3.1. Malaria Parasites
    • 9.3.2. Toxoplasma Gondii
  • 9.4. Viral
    • 9.4.1. Coronavirus
    • 9.4.2. Influenza Virus
    • 9.4.3. Norovirus
    • 9.4.4. Respiratory Syncytial Virus

10. Healthcare-associated Infectious Disease Diagnostics Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Serum
    • 10.1.2. Whole Blood
  • 10.2. Cerebrospinal Fluid
  • 10.3. Respiratory
    • 10.3.1. Bronchoalveolar Lavage
    • 10.3.2. Nasopharyngeal Swabs
    • 10.3.3. Sputum
  • 10.4. Urine
    • 10.4.1. Catheterized Urine
    • 10.4.2. Midstream Urine
  • 10.5. Wound Swabs
    • 10.5.1. Deep Tissue Samples
    • 10.5.2. Surface Swabs

11. Healthcare-associated Infectious Disease Diagnostics Market, by End User

  • 11.1. Diagnostic Laboratories
    • 11.1.1. Independent Laboratories
    • 11.1.2. Reference Laboratories
  • 11.2. Hospitals
    • 11.2.1. Clinical Pathology Laboratories
    • 11.2.2. Microbiology Laboratories
  • 11.3. Point Of Care
    • 11.3.1. Clinics
    • 11.3.2. Emergency Departments
    • 11.3.3. Long Term Care Facilities

12. Healthcare-associated Infectious Disease Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Healthcare-associated Infectious Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Healthcare-associated Infectious Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Healthcare-associated Infectious Disease Diagnostics Market

16. China Healthcare-associated Infectious Disease Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. bioMerieux SA
  • 17.9. Danaher Corporation
  • 17.10. DiaSorin S.p.A.
  • 17.11. QIAGEN N.V.
  • 17.12. Roche Diagnostics International AG
  • 17.13. Siemens Healthineers AG
  • 17.14. Sysmex Corporation
  • 17.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY AEROBIC CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ANAEROBIC CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SENSITIVITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLOSTRIDIUM DIFFICILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PSEUDOMONAS AERUGINOSA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASPERGILLUS SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CANDIDA SPECIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CRYPTOCOCCUS NEOFORMANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MALARIA PARASITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TOXOPLASMA GONDII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CORONAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY NASOPHARYNGEAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CATHETERIZED URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MIDSTREAM URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DEEP TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SURFACE SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICAL PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY EMERGENCY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY LONG TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY POINT OF CARE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY FUNGAL, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY URINE, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY WOUND SWABS, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032